Moore Capital Management, LP Contrafect Corp Transaction History

Moore Capital Management, LP

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2021 May 17, 2021	BUY	$4.46 - $6.68 $1.34 Million - $2 Million	300,000 Added 100.0%	600,000 $2.88 Million
Q4 2020 Feb 16, 2021	SELL	$5.05 - $6.4 $757,500 - $960,000	-150,000 Reduced 33.33%	300,000 $1.52 Million
Q3 2020 Nov 16, 2020	SELL	$5.05 - $6.99 $252,500 - $349,500	-50,000 Reduced 10.0%	450,000 $2.38 Million
Q2 2020 Aug 14, 2020	BUY	$4.69 - $7.81 $2.35 Million - $3.91 Million	500,000 New	500,000 $3.2 Million

49.2K

Ticker CFRX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 39,332,700
Market Cap $1.18M
Description
ContraFect Corporation, a clinical-stage biotechnology company, discovers and develops therapeutic protein and antibody products for the treatment of life-threatening and drug-resistant infectious diseases in the United States. Its lead program includes Exebacase, a lysin, which is in Phase III clinical trials for the treatment of staphylococcus...

Get notified when there are updates to the investment portfolio of Moore Capital Management, LP, based on Form 13F filings with the SEC.

Stay updated on Moore Capital Management, LP with notifications on news.